title: Peripheral blood stem cell transplantation: critical review.
abstract: Autologous blood stem cell transplantations have been increasingly performed worldwide for almost ten years in place of autologous bone marrow transplantation and even of allogenic bone marrow transplantation. Several crucial issues were the subjects of impassioned controversies. Some of them are now satisfactorily answered while others still remain unresolved. First, it is now possible to conclude today that peripheral blood stem cells (PBSC) are undoubtedly capable of restoring short term hematopoiesis when reinfused after myeloablative therapy as well as even more rapidly than bone marrow stem cells, provided that they have been previously collected in sufficient amounts. On the opposite, it is still impossible to firmly prove that their very immature CD34+ cell subset, although in vitro functionally and phenotypically almost identical to their marrow counterpart, is actually responsible for sustained long term hematopoietic recovery, even if it is likely that these cells play a key role. Most of the time, using chemotherapy alone or a combination of chemotherapy and cytokine(s), mobilizing regimens allow collection of appropriate yields of PBSC with only a small number of apheresis cycles, provided that a sufficient number of residual stem cells remains to be stimulated, when, on the contrary, collection in steady-state is time-consuming and does not provide further accelerated post transplant hematopoietic recovery. It was initially hypothesized that PBSC could have a lower likelihood of tumoral contamination compared with bone marrow. In fact, biological as well as clinical data are discordant and probably depend largely on the type of disease, its evolutive history and its way of dissemination.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Research Institute of Hematology and Transfusion, Hasenrain Hospital, Mulhouse, France.
authors.forename: P R
authors.initials: PR
authors.lastname: Hénon
mesh_terms: D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009369:Neoplasms / Q000628:therapy; D014182:Transplantation, Autologous